Uncommon Cents Investing LLC Has $559,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Uncommon Cents Investing LLC increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 10,305 shares of the biopharmaceutical company’s stock after buying an additional 1,260 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Bristol-Myers Squibb were worth $559,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BMY. First Trust Direct Indexing L.P. raised its position in shares of Bristol-Myers Squibb by 52.1% during the first quarter. First Trust Direct Indexing L.P. now owns 22,320 shares of the biopharmaceutical company’s stock worth $1,210,000 after purchasing an additional 7,649 shares during the period. Cornerstone Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 6.6% during the first quarter. Cornerstone Wealth Management LLC now owns 15,392 shares of the biopharmaceutical company’s stock worth $835,000 after buying an additional 948 shares during the last quarter. Kovack Advisors Inc. lifted its stake in shares of Bristol-Myers Squibb by 32.4% in the first quarter. Kovack Advisors Inc. now owns 30,489 shares of the biopharmaceutical company’s stock valued at $1,653,000 after buying an additional 7,464 shares in the last quarter. Hudson Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 10.7% during the first quarter. Hudson Capital Management LLC now owns 68,494 shares of the biopharmaceutical company’s stock valued at $3,714,000 after buying an additional 6,641 shares during the last quarter. Finally, Abundance Wealth Counselors increased its position in shares of Bristol-Myers Squibb by 26.9% during the first quarter. Abundance Wealth Counselors now owns 26,690 shares of the biopharmaceutical company’s stock worth $1,447,000 after acquiring an additional 5,664 shares in the last quarter. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on BMY shares. Wells Fargo & Company raised their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, BMO Capital Markets dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Stock Performance

BMY traded down $0.39 during trading hours on Thursday, hitting $40.06. The stock had a trading volume of 9,131,450 shares, compared to its average volume of 16,023,750. Bristol-Myers Squibb has a 1 year low of $39.63 and a 1 year high of $65.38. The company’s fifty day simple moving average is $42.46 and its 200 day simple moving average is $47.91. The stock has a market cap of $81.21 billion, a PE ratio of -12.92, a price-to-earnings-growth ratio of 13.84 and a beta of 0.44. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $2.05 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.99%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.